MenüForum-NavigationForumMitgliederAnmeldenRegistrierenForum-Breadcrumbs - Du bist hier:ForumFlohmarkt: KleidungDarkweb mixerAntwortenAntworten: Darkweb mixer <blockquote><div class="quotetitle">Zitat von Gast am 24. März 2026, 14:13 Uhr</div>[url=https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPAMED%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMED%20L130000429680&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord ]Zoya Demidenko[/url]: Scientist in Tumor Studies [url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026126 ]Zoya Demidenko[/url] is a recognized investigator affiliated with the Unit of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she conducted research at the NIH and New York Medical College, building a strong base in life science study. Her scientific work encompasses multiple critical fields, encompassing the PI3K/AKT/mTOR molecular pathway, cell cycle control, biological aging, and cancer science. As of now, she has co-authored more than 46 academic articles, which have accumulated over 4,100 citations — a indicator to the significance of her research. Among her most significant discoveries lies in understanding the pathways of cellular senescence. Her studies revealed that when the cell cycle is halted but cellular expansion proceeds, cells experience senescence. Importantly, [url=https://aacrjournals.org/cancerres/article/65/16/7386/518098/Depletion-of-Mutant-p53-and-Cytotoxicity-of?guestAccessKey= ]Zoya Demidenko[/url] demonstrated that this transition is inhibited by medication using compounds such as mTOR inhibitors. [url=https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPAMED%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMED%20L130000429680&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord ]Zoya Demidenko[/url] has also contributed considerably to cancer treatment research, especially in the area of selective cell protection — a approach aimed at protecting normal tissue from anticancer drugs while leaving cancer cells vulnerable. This method holds considerable hope for reducing the toxic effects of oncological therapy. Across her professional journey, Demidenko has collaborated with top investigators worldwide, including Dr. Mikhail Blagosklonny. Her publications is published in leading journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene. Holding an h-index of 33, [url=https://www.tandfonline.com/doi/abs/10.4161/cbt.4.4.1702 ]Zoya Demidenko[/url] is recognized as a widely cited contributor in modern cancer science, whose results keep to shape our understanding of the way cells grow old, resist treatment, and how cancer may be more effectively targeted. https://www.pinterest.com/zoyademidenko/ </blockquote><br> Abbrechen
